Current Status of Semaglutide Injection andDevelopment Prospects in China

Authors

  • Jianqiao Wen

DOI:

https://doi.org/10.61173/qr7sqa05

Keywords:

Semaglutide injection, obese, weight management

Abstract

Obesity is a global issue that closely affects public health, and China’s obesity rate is among the highest in the world. Recently, Semaglutide injection was approved for marketing in China as the first weekly formulation for long-term weight control. This review consolidates and analyzes various types of research related to Semaglutide regarding weight loss, to comprehensively describe the different aspects of the drug. As a glucagon-like peptide 1 receptor agonists (GLP-1RA), Semaglutide works by mimicking the action of innate hormone to enhance the cell signaling activity and corresponding outcome. It has been approved to effectively reduce weight and improve weight-related factors in overweight or obese patients with a guaranteed safety profile. Comparing to traditional methods of losing weight, this medication is time and effort-saving, which makes it highly competitive in this field. Although there are still unsolved issues and challenges faced by the drug, such as high price and acceptance among doctors and patients, it is highly likely to become a new and anticipated method of weight management in China

References

[1] Notice of the General Office of the National Health Commission on the Issuance of Four Dietary Guidelines, Including the Dietary Guidelines for Adults with Hyperuricemia and Gout (2024 Edition).; 2024. Accessed June 28, 2024. http:// www.nhc.gov.cn/sps/s7887k/202402/4a82f053aa78459bb88e35f 812d184c3.shtml

[2] Safety 365-the Secret of Weight Loss Pills.; 2018. Accessed June 28, 2024. https://www.nmpa.gov.cn/xxgk/yjshp/ yjshpkp/20180129111601768.html

[3] Semaglutide Approved for Weight Loss in China, with Global Sales Expected to Exceed US$4.5 Billion in 2023. People’s Daily. Published June 25, 2024. Accessed June 28, 2024. https://baijiahao.baidu.com/s?id=1802839039607298002 &wfr=spider&for=pc

[4] Semaglutide injection: MedlinePlus Drug Information. MedlinePlus. Published August 15, 2022. Accessed June 30, 2024. https://medlineplus.gov/druginfo/meds/a618008.html

[5] GLP-1 RA Education. Novonordisk. Published April 2024. Accessed June 30, 2024. https://pro.novonordisk.com/diseasearea/diabetes/understanding-glp1/glp-1-shift/glp-1-ra-education. html

[6] Dowarah J, Singh VP. Anti-diabetic Drugs Recent Approaches and Advancements. Bioorganic & Medicinal Chemistry. 2020;28(5):115263. doi:10.1016/j.bmc.2019.115263

[7] Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the Treatment of Obesity. Trends in Cardiovascular Medicine. 2021;33(3). doi:10.1016/j.tcm.2021.12.008

[8] McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews. 2020;42(2):101-132. doi:10.1210/endrev/bnaa032

[9] Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – state-of-theart. Molecular Metabolism. 2021;46:101102. doi:10.1016/ j.molmet.2020.101102

[10] Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity. JAMA Network Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982

[11] Liu Y, Li R, Hao N, Li W. Clinical Trial of Semaglutide and Saxagliptin Combined with Metformin in Thetreatment of Patients with Type 2 Diabetes Mellitus with Abdominal Obesity. Wanfangdata. 2024;40(10). doi:10.13699/ j.cnki.1001-6821.2024.10.002

[12] The First “weight Loss injection” Has Been Approved in China and Can Be Purchased and Used with a doctor’s Prescription. People’s Daily. Published July 6, 2023. Accessed June 30, 2024. https://m.baidu.com/bh/m/detail/ ar_9820090728169655047

[13] Xu H, Zhao X, Xu H, Yang W. Comparison of the Effects of Semaglutide and Liraglutide in the Treatment of Diabetes Mellitus Complicated with Obesity. Wanfangdata. 2023;30(2). doi:10.15900/j.cnki.zylf1995.2024.02.029

[14] Rubino DM, Greenway FL, Khalid U, et al. Effect of Dean&Francis Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022;327(2):138. doi:10.1001/jama.2021.23619

[15] Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021;12. doi:10.3389/fendo.2021.645563

[16] Bi Y, Zhang H, Li Y. Efficacy and Safety of Semaglutide in the Treatment of Overweight or Obese Adults without Diabetes: A Meta-analysis. Wanfangdata. Published March 13, 2023. Accessed July 1, 2024. doi:10.3870/ j.issn.1672-0741.2023.01.016

[17] Why Wegovy®? | Wegovy® (semaglutide) Injection 2.4 mg. Wegovy. Published 2024. Accessed June 30, 2024. https:// www.wegovy.com/about-wegovy/why-wegovy.html?

[18] Zeng W, Jin Q, Wang X. Reassessing the Effects of Dietary Fat on Cardiovascular Disease in China: A Review of the Last Three Decades. Nutrients. 2023;15(19):4214-4214. doi:10.3390/ nu15194214

[19] Wei Z, Dong Z, Wang C. Dilemma and Breakthrough in the Advancement of Bariatric and Metabolic Surgery in China. Wanfangdata. Published online May 14, 2024. doi:10.3760/cma. j.cn441530-20230815-00049

[20] Pei G, Wang Z, Xie K, Ma Z. Research Hotspots and Trends of Exercise Intervention for Obesity in China:Based on Citespace Visualized Graph Analysis. Wanfangdata. Published online November 8, 2023. doi:10.3969/j.issn.1007-0834.2023.03.014

Downloads

Published

2024-10-29

Issue

Vol. 2 No. 5 (2024): Volume 2, Issue 5

Section

Articles

License

Copyright (c) 2024 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.